![Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC](https://www.sawayapartners.com/wp-content/uploads/2017/11/Teva-1170x560.jpg)
Teva Announces Sale of Remaining Assets in Specialty Global Women's Health Portfolio for $1.38 Billion – Sawaya Partners., LLC
![PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study](https://i1.rgstatic.net/publication/350438778_Safety_of_OvaleapR_compared_to_Gonal-fR_in_real-world_clinical_practice_results_from_the_safety_of_ovaleap_follitropin_alfa_SOFIA_study/links/605f393b92851cd8ce6f9f4f/largepreview.png)
PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study
Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology, Nummer 2/2017
![Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5427053/bin/40268_2017_182_Fig1_HTML.jpg)
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC
![Frontiers | Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study | Endocrinology Frontiers | Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study | Endocrinology](https://www.frontiersin.org/files/Articles/632674/fendo-12-632674-HTML/image_m/fendo-12-632674-g001.jpg)
Frontiers | Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study | Endocrinology
![Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study ... Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study ...](https://media.springernature.com/lw150/springer-static/cover/journal/12958/18/1.jpg?as=jpg)